Core Viewpoint - The company "好想你" has shown significant improvement in profitability, with a notable recovery in its financial performance driven by cost advantages and effective expense management [2][3][4]. Financial Performance Summary - In 2024, total revenue was 1.67 billion yuan, a decrease of 3% year-on-year, with a net loss of 72 million yuan compared to a loss of 52 million yuan in 2023. The first quarter of 2025 saw total revenue of 413 million yuan, a decrease of 16%, but a net profit of 40 million yuan, an increase of 216% year-on-year [2]. - The gross profit margin for 2024 and Q1 2025 was 22.62% and 33.97%, respectively, indicating a recovery in profitability as high-cost raw materials have been consumed [3]. Cost Management and Profitability - The company has effectively reduced sales and management expense ratios, leading to improved net profit margins of -4.53% in 2024 and 9.62% in Q1 2025 [3]. - The company is expected to continue benefiting from lower raw material costs and reduced depreciation expenses, which will enhance profitability in the coming years [4]. Product and Channel Strategy - The revenue from red date products, health preservation products, and other categories in 2024 was 1.22 billion yuan, 69 million yuan, and 320 million yuan, respectively, with a focus on developing differentiated and technologically advanced products [3]. - Offline channel revenue increased by 3% to 1.14 billion yuan, driven by new retail channels, while e-commerce revenue decreased by 16% to 475 million yuan due to channel relocation [3]. Earnings Forecast - The company is projected to have earnings per share (EPS) of 0.02 yuan, 0.17 yuan, and 0.27 yuan for 2025, 2026, and 2027, respectively, with current price-to-earnings (PE) ratios of 502, 70, and 44 times [4].

Investment Rating - The report maintains a "Buy" investment rating for the company [9] Core Views - The company has shown significant improvement in net profit, with a notable recovery in profitability driven by the consumption of high-cost raw materials and effective cost control measures [2][3] - The company is focusing on optimizing its product structure and enhancing cost management in e-commerce channels, which is expected to lead to improved profitability [3] Summary by Sections Financial Performance - In 2024, total revenue was 1.67 billion yuan, a decrease of 3% year-on-year, with a net loss of 72 million yuan compared to a loss of 52 million yuan in 2023. The first quarter of 2025 saw total revenue of 413 million yuan, a decrease of 16%, but a net profit of 40 million yuan, an increase of 216% [1][9] - The company distributed a total cash dividend of 611 million yuan as of December 31, 2024, marking a historical high in dividend payout [1] Profitability and Cost Management - Gross margins for 2024 and Q1 2025 were 22.62% and 33.97%, respectively, with a recovery in profitability expected as high-cost raw materials are depleted and new procurement costs are at historical lows [2] - The sales expense ratio decreased by 0.1 percentage points in 2024 and 1 percentage point in Q1 2025, while the management expense ratio decreased by 1 percentage point and 0.1 percentage points, respectively, indicating effective cost control [2] Product and Channel Strategy - Revenue from red date products, health preservation products, and other categories in 2024 was 1.22 billion yuan, 69 million yuan, and 320 million yuan, respectively, with a focus on developing differentiated and technologically advanced red date products [3] - Offline channel revenue increased by 3% to 1.14 billion yuan in 2024, driven by new retail channels, while e-commerce revenue decreased by 16% to 475 million yuan due to channel relocation impacts [3] Earnings Forecast - The company is expected to see continued improvement in profitability due to lower raw material costs and the expiration of certain depreciation expenses, with projected EPS for 2025-2027 at 0.02, 0.17, and 0.27 yuan, respectively [9]

Investment Rating - Maintain Outperform rating with a target price adjusted to RMB 32.50 [1][9] Core Views - The company has cleared goodwill impairment risks and is expanding plasma collection stations through both organic and external growth, establishing a foundation for future growth. The potential impact of tariffs on imported albumin may benefit domestic albumin products [1][9] - The company reported a full-year revenue of RMB 1.74 billion, a decrease of 34.58%, while net profit increased by 67.18% to RMB 397 million, primarily due to a low base from goodwill impairment in 2023 [1][9] - The product structure is continuously optimized, with blood product revenue growing by 4.32% to RMB 1.51 billion, despite a slight decline in gross profit margin [1][9] Financial Summary - Revenue and profit forecasts for 2024-2027 show a recovery trend, with net profit expected to reach RMB 753 million by 2027, reflecting a compound annual growth rate [3][6] - The company has a projected EPS of RMB 1.16 for 2025 and RMB 1.50 for 2027, with a PE ratio of 28X for 2025 [1][9] - The company has 20 operating plasma stations and plans to increase plasma collection volume to 630.6 tons in 2024, a 10.4% increase [1][9]

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price adjusted to RMB 32.50 [1][9]. Core Insights - The company has cleared goodwill impairment risks and is expanding its plasma collection stations through both organic growth and acquisitions, establishing a foundation for future growth. The potential impact of tariffs on imported albumin may benefit domestic albumin products [1][9]. - The company reported a full-year revenue of RMB 1.74 billion in 2024, a decrease of 34.58%, while net profit increased by 67.18% to RMB 397 million, primarily due to a low base from goodwill impairment in 2023 [1][9]. - The product structure is continuously optimized, with blood product revenue growing by 4.32% to RMB 1.51 billion in 2024, despite a slight decline in gross profit margin [1][9]. Financial Summary - Revenue and profit forecasts for the upcoming years have been adjusted, with 2025 EPS projected at RMB 1.16 and 2026 EPS at RMB 1.33, while a new forecast for 2027 EPS is set at RMB 1.50 [1][9]. - The company is expected to maintain a steady growth trajectory, with plasma collection volume projected to reach 630.6 tons in 2024, reflecting a 10.4% increase [1][9]. - The financial outlook includes a projected net profit of RMB 585 million for 2025, with a net profit margin expected to improve over the years [1][9].

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 6.64 CNY per share [6][4]. Core Views - The company reported a revenue of 322.12 billion CNY in 2024, a decrease of 6.60% year-on-year, and a net profit attributable to shareholders of 7.36 billion CNY, down 38.36% year-on-year [1][4]. - In Q1 2025, the company achieved a revenue of 72.88 billion CNY, a decrease of 9.82% year-on-year, but the net profit increased by 26.37% year-on-year to 2.43 billion CNY [1][2]. Summary by Sections Financial Performance - In 2024, the company's steel sales volume was 51.59 million tons, a slight decline of 0.6% year-on-year, while the average product price was 4,507 CNY per ton, down 6.89% year-on-year [2][3]. - The gross profit margin for Q1 2025 improved to 7.22%, an increase of 2.09 percentage points year-on-year [2][3]. Dividend Policy - The company plans to distribute a cash dividend of 0.10 CNY per share, totaling approximately 2.15 billion CNY, with an overall annual distribution of 4.52 billion CNY, resulting in a dividend payout ratio of 61.34% [2][3]. Future Outlook - The company is focused on optimizing its product structure, with a sales volume of high-end products increasing by 9.6% year-on-year [3]. - The company aims to achieve a sales target of 52.24 million tons of steel in 2025, representing a 1.3% increase year-on-year [2][3]. - The company has made significant progress in international expansion, with export sales reaching 6.07 million tons in 2024, up 3.9% year-on-year [3].

Investment Rating - The report maintains a "Recommended" rating for the company [6][4]. Core Views - The company experienced a significant improvement in Q1 profitability, with a continuous optimization of product structure [1]. - Despite a decrease in revenue and net profit for 2024, the first quarter of 2025 showed a recovery in net profit [1][2]. - The company is focusing on high-end product development and international expansion, which are expected to drive future growth [3][4]. Summary by Sections Financial Performance - In 2024, the company achieved revenue of 322.116 billion yuan, a year-on-year decrease of 6.60%. The net profit attributable to shareholders was 7.362 billion yuan, down 38.36% year-on-year [1]. - For Q1 2025, revenue was 72.880 billion yuan, a decrease of 9.82% year-on-year, while net profit increased by 26.37% year-on-year to 2.434 billion yuan [1][2]. Sales and Margins - Steel sales in 2024 were 51.59 million tons, a slight decline of 0.6% year-on-year. The company aims to sell 52.24 million tons in 2025, a 1.3% increase [2]. - The average product price in 2024 was 4,507 yuan/ton, down 6.89% year-on-year. The gross margin improved to 7.22% in Q1 2025, up 2.09 percentage points year-on-year [2]. Dividend Policy - The company plans to distribute a cash dividend of 0.10 yuan per share, totaling approximately 2.15 billion yuan, with an overall payout of 4.516 billion yuan for the year, resulting in a dividend payout ratio of 61.34% [2]. Future Outlook - The company is optimizing its product structure, with a focus on high-strength steel and silicon steel products, which are gaining market share [3]. - Key projects are progressing, including the establishment of high-end steel production capacities [3]. - The company is expanding its international presence, with a notable increase in export volumes [3]. Profit Forecast - The company is expected to achieve net profits of 9.830 billion yuan, 11.122 billion yuan, and 12.427 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 15, 13, and 12 [4][5].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a significant increase in performance for 2024, with operating revenue reaching 25.73 billion yuan, a year-on-year growth of 22.4%. The net profit attributable to shareholders was 3.32 billion yuan, up 498.1% year-on-year, and the net profit excluding non-recurring items was 3.06 billion yuan, a staggering increase of 2114.7% [6][7] - The growth in revenue and profit is primarily attributed to the recovery in demand from the high-end smartphone and automotive markets, along with an increase in market share [7] - The company’s image sensor (CIS) business achieved operating revenue of 19.19 billion yuan, accounting for approximately 74.8% of total revenue, with a year-on-year growth of 23.5% and a gross margin of 34.5%, up 10.5 percentage points [10] Financial Performance Summary - For 2024, the company achieved: - Operating revenue: 25.73 billion yuan - Year-on-year revenue growth: 22.4% - Net profit attributable to shareholders: 3.32 billion yuan - Year-on-year net profit growth: 498.1% - Gross margin: 29.4%, an increase of 7.7 percentage points [6][11] - Forecasted financials for 2025-2027: - Net profit attributable to shareholders: 4.69 billion yuan in 2025, 6.13 billion yuan in 2026, and 8.42 billion yuan in 2027 - Corresponding EPS: 3.86 yuan in 2025, 5.04 yuan in 2026, and 6.92 yuan in 2027 [7][11]

本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 妙可蓝多25Q1实现营业收入12.3亿元，同比+6.3%（调整后）；归母净利润0.8亿元，同比+114.9%（调整 后）；扣非归母净利润0.6亿元，同比+110.2%。 并表后奶酪业务收入同比增加明显 1）分产品看：25Q1奶酪/液态奶/贸易收入分别为10.30/0.95/1.01亿元，和蒙牛奶酪并表前的24Q1各业务收 入分别为7.85/0.81/0.82亿元。2）分渠道看：25Q1经销/直营/贸易收入分别为9.59/1.65/1.01亿元，并表前 的24Q1各渠道收入分别为7.35/1.31/0.82亿元。3）分地区看：25Q1北区/中区/南区收入分别为4.64/5.14/ 2.48亿元，并表前的24Q1各地区收入分别为3.74/3.87/1.87亿元。截 ...

点击注册小程序 查看完整报告 特别申明： 与蒙牛协同推进降本增效，上新加快逐步贡献业绩增量 事件： 妙可蓝多25Q1实现营业收入12.3亿元，同比+6.3%（调整后）；归母净利润0.8亿元，同比+114.9%（调整 后）；扣非归母净利润0.6亿元，同比+110.2%。 并表后奶酪业务收入同比增加明显 1）分产品看：25Q1奶酪/液态奶/贸易收入分别为10.30/0.95/1.01亿元，和蒙牛奶酪并表前的24Q1各业务收 入分别为7.85/0.81/0.82亿元。2）分渠道看：25Q1经销/直营/贸易收入分别为9.59/1.65/1.01亿元，并表前 的24Q1各渠道收入分别为7.35/1.31/0.82亿元。3）分地区看：25Q1北区/中区/南区收入分别为4.64/5.14/ 2.48亿元，并表前的24Q1各地区收入分别为3.74/3.87/1.87亿元。截至25Q1末，北区/中区/南区经销商数量 分别为3662/2424/1960个，总计8046个，较24年末分别增加111/106/32个，总计净增加249个，经销商数量 持续增加。 产品结构优化及积极控费下，25Q1归母净利率同比改善 1）毛利率：25Q1 ...

事件： 华友钴业于 2025年4 月 18 日晚发布 2 024年年报及 2025年一季报 ， 2024年 实现营收 609.5 亿元，同比 下降 8 %，归母净利润 41.5 亿元，同比增长 24 %；扣非归母净利润为 37.95亿元，同比增长22.7% 。 2 02 5Q1实现营收178.4亿元，同比增长19%；归母净利润12.5亿元，同比增长139.7%。 点评： 金属：镍板块利润释放 2 024年公司镍产品出货量（含内部自供） 18.4万吨，同比增长46%，主要由于印尼华飞12万吨镍湿法冶炼 项目2024Q1实现达产，产量逐步释放；镍产品及中间品毛利合计占公司毛利的52%。钴产品出货量4.7万 吨（含内部自供），同比增长13%；铜产品销量9.0万吨，同比增长2.8%。 津巴布韦 Arcadia 锂矿项目实 现锂精矿出货量约40万吨，同比增长41%。 锂电材料：减少低盈利产品出货，优化产品结构 点击注册小程序 查看完整报告 （ 1 ） 2024年 锂电正极前驱体出货量超 12万吨（含三元前驱体和四氧化三钴，包括内部自供），正极材 料出货量超9万吨（含内部自供及参股公司权益量），因公司主动减少部分低盈利产 ...